Liver Transplantation Clinical Trial
Official title:
Record and Analyze the Data of Patient Undergoing Anesthesia for Liver Transplantation From Patient Monitoring Instruments
To record the intra-operative digital data from the standard monitoring instruments containing cardiovascular system information, and from depth-of-anesthesia monitoring modules (Bispectral index, Entropy module, Surgical Plethysmography Index) containing neurological system information captured in the patient monitor, as well as the physiological data regarding anesthetic dosage, respiratory gas analysis and the standard monitoring requirement of anesthesia. All above data comes from patients undergoing liver transplantation surgery for medical reason. The investigators also record the precise time points of detail surgical stages during the surgery . Clinical data collected from these monitoring instrument will be used to gain more understanding of the complex interaction between anesthetic effect, surgical procedure, autonomic response and drug modeling. The goal is to obtain the clinical value of various features extracted from physiological data, in particular the waveform data from cardiovascular system.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | October 2020 |
Est. primary completion date | October 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Adult patient undergoing living donor liver transplant with MELD score < 20 Exclusion Criteria: - Vulnerable populations per institutional regulation, including under-age, history of drug abuse, HIV carrier, AIDS, aborigine, prisoner. - Unable to communicate, for example hepatoencephalopathy, on endotracheal tube with ventilator support - Complicated liver transplant procedure, for example domino liver donation - Poor liver graft condition, donor have fatty liver (>15% adipose tissue by liver biopsy pathologic report) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Taipei Veterans General Hospital, Taiwan | Duke University |
Wang SC, Lin HT, Chang KY, Mandell MS, Ting CK, Chu YC, Loong CC, Chan KH, Tsou MY. Use of higher thromboelastogram transfusion values is not associated with greater blood loss in liver transplant surgery. Liver Transpl. 2012 Oct;18(10):1254-8. doi: 10.1002/lt.23494. — View Citation
Wang SC, Teng WN, Chang KY, Susan Mandell M, Ting CK, Chu YC, Loong CC, Chan KH, Tsou MY. Fluid management guided by stroke volume variation failed to decrease the incidence of acute kidney injury, 30-day mortality, and 1-year survival in living donor liver transplant recipients. J Chin Med Assoc. 2012 Dec;75(12):654-9. doi: 10.1016/j.jcma.2012.08.007. Epub 2012 Nov 17. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Correlation between SPI value and heart rate variability at predefined surgical step | Surgical Pleth Index (SPI) is a newly developed pain monitor derived from analysis of pulse oximetry signal. Such analysis is based on heart rate variability for autonomic nervous system activity. However the accuracy of SPI is questioned for interference of vasculopathy upon pulse oximeter signal quality. For liver transplant, there are three stages as followed: dissection phase, anhepatic phase and neohepatic phase. Liver plays an important role in renin-angiotensin-aldosterone system which affects the vessel tone. Therefore, the investigators will explore the correlation of heart rate variability calculated from ECG QRS complex and SPI at these three different stages in liver transplant. The Spearman rank correlation > 0.7 and the prediction probability vale > 0.7 are positive outcome result. | During dissection, anhepatic and neohepatic phases. Of IVC clamp, reperfusion, and hepatic artery anatomises, the moment, 10 minutes before, 15 minutes after, 1 hour and 2 hours after the surgical steps. | |
Primary | Correlation between Arterial waveform and Flotrac(TM) cardiac output analysis | Liver plays an important role in renin-angiotensin-aldosterone system which affects vessel tone. At anhepatic phase in liver transplant, it was noticed that the reflected wave in arterial waveform disappears but the forward waveform remains. The investigators hypothesize that this is caused by the inability to transform angiotensinogen without liver. Flotrac by Edward lifescience is a device to calculate cardiac output and stroke volume variation from arterial waveform. The investigators will explore the correlation of Flotrac cardiac output with arterial waveform in anhepatic phase. The arterial waveform analysis includes area under arterial waveform, the slope for forward wave and pulse pressure. Also high dimensional method including diffusion map and locally linear embedding will be used to transform the whole waveform into more meaningful quantitative indices. The Spearman rank correlation > 0.7 and the prediction probability vale > 0.7 are positive outcome result. | During dissection, anhepatic and neohepatic phases. Of IVC clamp, reperfusion, and hepatic artery anatomises, the moment, 10 minutes before, 15 minutes after, 1 hour and 2 hours after the surgical steps. | |
Secondary | Correlation between waveform analysis, graft and patient survival | Liver plays an important role in renin-angiotensin-aldosterone system which affects vessel tone. At anhepatic phase in liver transplant, it was noticed that the reflected wave in arterial waveform disappears but the forward waveform remains. The investigators hypothesize that this is caused by unabling to transform angiotensinogen without liver. The investigators hypothesized that the reflected wave in arterial waveform could represent graft function. Therefore the investigator will analyze reflected waveform after reperfusion and record patient outcome as 30-day mortality, ventilator use, ICU stay and kidney injury. The Spearman rank correlation > 0.6 is positive outcome result. | For first week after operation, data will be recorded daily including INR, blood transfusion, serum creatinine and PaO2/Fio2. Kidney and lung injury will be specified. Also the investigators will record days for ICU stay and ventilator use. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04180735 -
Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
|
||
Completed |
NCT01011205 -
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
|
Phase 3 | |
Completed |
NCT01888432 -
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
|
Phase 3 | |
Recruiting |
NCT04203004 -
HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)
|
N/A | |
Recruiting |
NCT04564313 -
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
|
Phase 1 | |
Withdrawn |
NCT03596970 -
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
|
Phase 3 | |
Not yet recruiting |
NCT02544906 -
Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation
|
N/A | |
Completed |
NCT03133065 -
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
|
Phase 4 | |
Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Terminated |
NCT01445236 -
Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance
|
N/A | |
Completed |
NCT00938860 -
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
|
Phase 4 | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
Completed |
NCT00456235 -
Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors
|
Phase 4 | |
Terminated |
NCT00585858 -
Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant
|
N/A | |
Recruiting |
NCT00147459 -
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation
|
N/A | |
Terminated |
NCT00161356 -
Ambisome in Liver Transplant Patients
|
Phase 4 | |
Withdrawn |
NCT00167492 -
Enteric Coated Myfortic for Liver Transplant Recipients
|
Phase 4 |